Please use this identifier to cite or link to this item:
|Title:||Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study.||Austin Authors:||Ong, Sean;Pascoe, Claire;Kelly, Brian D ;Ballok, Zita;Webb, David ;Bolton, Damien M ;Murphy, Declan;Sengupta, Shomik ;Bowden, Patrick;Lawrentschuk, Nathan||Affiliation:||EJ Whitten Foundation Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia.
Olivia Newton-John Cancer Wellness and Research Centre
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Department of Nuclear Medicine, Richmond Medical Imaging, Richmond, VIC 3121, Australia.
Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3051, Australia
Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia.
|Issue Date:||13-Dec-2022||Date:||2022||Publication information:||Cancers 2022; 14(24)||Abstract:||PSMA PET-CT scans are now recommended in international urological guidelines for primary staging and re-staging of prostate cancer. However, there is little published literature on the clinical outcomes for patients after treatment decisions made using PSMA PET-CT results. This is a multisite, prospective cohort study investigating the clinical outcomes of men who received treatment plans based on PSMA PET-CT results for primary staging. Men with biopsy proven prostate cancer received a PSMA PET-CT scan for primary staging. Treatment plans were recommended by multidisciplinary teams (MDT). After treatment, these men were followed with 6 monthly PSA tests and imaging or biopsies if recommended by MDT. The primary outcome was treatment progression defined as the addition or change of any treatment modalities such as androgen deprivation therapy, radiation therapy or chemotherapy. In total, 80% of men did not have any treatment progression after enactment of treatment based on PSMA PET-CT primary staging results at 29 months of follow up. Men who had distant nodes seen on PSMA PET-CT had a 5 times increased risk of treatment progression. Larger studies with longer follow up are needed to validate our results and optimise the way clinicians use PSMA PET-CT results to guide management.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/31869||DOI:||10.3390/cancers14246134||ORCID:||0000-0003-1117-2409
|Journal:||Cancers||PubMed URL:||36551620||Type:||Journal Article||Subjects:||PSMA PET
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 10, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.